Executive Summary

Start of Phase II trials of the implantable contact lens for hyperopia (farsightedness) is announced by the company March 25. FDA's approval allows the company to expand its investigator base from four to 10 surgeons and to implant 62 ICLs in patients. A Phase I hyperopia trial conducted outside the U.S. included 10 patients with an average preoperative hyperopia of 6.05 diopters. Results showed seven of the ten patients with 20/20 vision or better without glasses or contact lenses and all 10 had 20/40 or better following the procedure, the company claims. Placed in the eye during a suture-less outpatient procedure, the ICL is currently in Phase II trials for myopia. The company hopes to commence Phase III of that trial in the near future. The company received CE mark approval for the ICL in July